Search

Displaying results 6601 - 6610 of 7893 in total
  1. Drug

    Leptazoline B

    go.drugbank.com/drugs/DB15552
    Experimental

    Leptazoline B is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline C], and [Leptazoline D].

    Synonyms: Leptazoline B
  2. Drug

    Leptazoline C

    go.drugbank.com/drugs/DB15553
    Experimental

    Leptazoline C is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline B], and [Leptazoline D].

  3. Drug

    Reloxaliase

    go.drugbank.com/drugs/DB15560
    Investigational

    Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_.

  4. Drug

    FLX475

    go.drugbank.com/drugs/DB15570
    Investigational

    FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.[L9875]

  5. Drug

    Echinomycin

    go.drugbank.com/drugs/DB15582
    Experimental

    Echinomycin is a cytotoxic polypeptide quinoxaline antibiotic isolated from _Streptomyces echinatus_ that binds to DNA and inhibits RNA synthesis.

    Synonyms: Quinomycin A
  6. Drug

    ORG-31710

    go.drugbank.com/drugs/DB15585
    Experimental

    ORG-31710 is a progestational hormone antagonist.

  7. Drug

    Fluzoparib

    go.drugbank.com/drugs/DB15637
    Investigational

    Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

  8. Drug

    Gusacitinib

    go.drugbank.com/drugs/DB15670
    Investigational

    Gusacitinib is under investigation in clinical trial NCT02550678 (A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma).

  9. Drug

    Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15682
    ApprovedInvestigational

  10. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    [L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection. … BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.